進階搜尋


下載電子全文  
系統識別號 U0026-2104201416591600
論文名稱(中文) 利用基因體及醣質體方法探索鑑定口腔癌腫瘤新型腫瘤標誌
論文名稱(英文) Genomic and glycomic identifications of novel tumor markers for oral cancer
校院名稱 成功大學
系所名稱(中) 基礎醫學研究所
系所名稱(英) Institute of Basic Medical Sciences
學年度 102
學期 2
出版年 103
研究生(中文) 陳怡婷
研究生(英文) Yi-Ting Chen
學號 S58971340
學位類別 博士
語文別 英文
論文頁數 145頁
口試委員 指導教授-張權發
召集委員-陳玉玲
召集委員-謝達斌
口試委員-楊慕華
口試委員-邱繼輝
中文關鍵字 口腔癌  轉移  AGR2蛋白  核心–岩藻醣化 
英文關鍵字 Oral cancer  Metastasis  Anterior gradient 2  Core-fucosylation 
學科別分類
中文摘要 目的:近年來,口腔癌為全球死亡率遞增的最常見的腫瘤之一,特別是在台灣;預防遠端器官的癌症轉移對於促進患者的生存率是可行的治療方法之一。另外,腫瘤細胞所表現特殊醣類結構曾被報導可以調節癌化進展,包括促進癌細胞的增殖、生長、粘附、行移及轉移等步驟。在此,我們試圖利用基因體及醣質體方法探索口腔癌癌化過程中新的治療標的治療標的或是腫瘤標記 。
實驗設計: 從人類口腔癌HSC-3以體外侵犯試驗分離並篩選出一高轉移性亞群細胞,接著利用基因表現微陣列技術進行比對尋找出基因圖譜中相異的醣基轉移酶基因或是其他基因,並藉由免疫組織化學染色法驗證所發現的基因的表現量。此外,純化細胞所表現的氮基醣類,並藉由基質輔助雷射脫附離子化-飛行時間質譜儀進行氮基醣類結構預測分析。
結果:我們利用侵犯試驗成功地從HSC-3細胞中,篩選分離出一具有相同遺傳物質但轉移性較高的亞群細胞(HSC-3-5細胞)。HSC-3-5細胞因細胞骨架重組伴隨導致形成上皮-間質轉化而有較高的轉移能力,同時,經由動物實驗證實HSC-3-5細胞更具腫瘤形成及轉移等能力。另外,進行HSC-3 及HSC-3-5細胞基因微陣列分析比對,鑑別指出促進癌化訊息調控的anterior gradient 2 (agr2)基因在HSC-3-5細胞中高度表現,藉由109 位口腔癌病人檢體驗證AGR2蛋白高度表達與癌症轉移有高靈敏度但低特異度的正向相關連性,AGR2蛋白可能是口腔癌轉移診斷的靈敏性生物標誌。同時,從微陣列基因表現分析在HSC-3-5細胞中,調控核心–岩藻醣化過程的fut8基因表現量較低,並從40位口腔癌病人檢體的免疫組織染色證實在轉移性腫瘤組織中核心-岩藻醣化現象較低。此外, AGR2蛋白高度表現的現象結合核心–岩藻醣化減量的現象,將可以改善對腫瘤轉移的陽性及陰性預測值。
結論:我們認為AGR2蛋白具潛力成為轉移性口腔癌細胞新的靈敏型腫瘤標誌,而且結合核心–岩藻醣化現象及AGR2蛋白,將有助於改善腫瘤轉移的陽性和陰性預測值。
英文摘要 Purpose: Oral cancer is one of the most commonly diagnosed tumors with increasing mortality worldwide, especially in Taiwan in recent years. Prevention of oral squamous carcinoma cancer metastasis to improve the overall survival has provided the rationale for biomarker development. In addition, specific glycans expressed in tumor cells have been identified as key mediators during the various progression steps of tumor including proliferation, growth, cell-cell adhesion, migration, and metastasis. Here, we are trying to explore novel therapeutic targets or tumor markers during oral cancer progression by genomics or glycomics approaches.
Experimental Design: A high metastatic sub-population was divided from human oral cancer HSC-3 by invasion assay in vitro. Gene expression microarray technology was performed to compare the different gene profiles, such as glycosyltransferases genes or others. Consequently, immunohistochemical staining was applied to verify expressions of identified genes. Further, N-glycans of cells were purified and subjected to Matrix-Assisted Laser Desorption Ionization –Time of Fight (MALDI-TOF) mass spectrometry analysis.
Results: We used Transwell invasion assay to successfully isolate a high-metastatic subpopulation, HSC-3-5 cells, which exhibited almost same genetic background with parental cells and higher metastatic capacities due to cytoskeletal rearrangement accompanied with epithelial mesenchymal transition. HSC-3-5 cells also showed tumorigenic and metastatic characteristics in vivo. In addition, anterior gradient 2 (agr2) gene, a pro-oncogenic signaling intermediate, was identified from gene expression profiles. Overexpression of AGR2 showed a high sensitivity, which positively correlated with metastasis in 109 oral cancer patients, and a poor specificity. AGR2 was likely a novel sensitive diagnostic marker for oral cancer metastasis. In the meanwhile, down-regulation of fut8 gene, which regulated the core-fucosylation process, was recognized in HSC-3-5 cells from the gene expression microarray and verified in metastatic tissues by 40 oral cancer patients of immunohistochemical staining. In addition, the positive and negative prediction values of metastasis could be improved through combination with decreased core-fucosylation and overexpression of AGR2.
Conclusions: AGR2 was suggested to be a novel sensitive biomarker for metastatic oral cancer. And combined core-fucosylation with AGR2 promoted the positive and negative predictive value of metastasis.
論文目次 中文摘要 I
Abstract III
誌謝 V
Index of Contents VI
Index of Table Information IX
Index of Figure Information X
Index of Supplemental Information XII
Contents 1
1. Introduction 1
1.1. Oral cancer 1
1.2. Oral cancer tumor markers 1
1.3. Tumor metastasis 2
1.4. Human Anterior Gradient 2 (AGR2) and AGR2 biological functions 4
1.5. Glycosylation and cancers 5
1.6. Fucosyltransferase 8 (FUT8) and core-fucosylation in cancer 7
2. Specific purpose and experimental flowchart 9
2.1. Specific purpose 9
2.2. Experimental flowchart 9
3. Materials and methods 12
3.1. Cell lines and tissue culture 12
3.2. Transwell Matrigel invasion assay 12
3.3. Invasion selection assay 13
3.4. Short tandem repeats (STR)- polymerase chain reaction (PCR) analysis 14
3.5. Wound healing assay 15
3.6. Real-time wound healing assay and signal cell tracking 15
3.7. Confocal microscopic analysis 16
3.8. Protein extraction and Western blot 16
3.9. In vivo spontaneous metastasis assay with heterotopic subcutaneous transplantation 17
3.10. Nested polymerase chain reaction (PCR) assay 18
3.11. In vivo experimental metastasis assay with intravenous transplantation 18
3.12. In vitro adhesion assay 19
3.13. MTT assay 19
3.14. Soft agar colony formation assay 20
3.15. In vivo spontaneous metastasis assay with orthotopic tongue transplantation 20
3.16. In vitro and in vivo gene expression microarray analysis 21
3.17. AGR2 siRNA transfection 21
3.18. Immunostaining analysis 22
3.19. Immunohistochemistry (IHC) analysis 23
3.20. Human oral cancer tissue array 24
3.21. N-glycan purification 24
3.22. N-glycans permethylation for Matrix-Assisted Laser Desorption Ionization –Time of Fight (MALDI-TOF) mass spectrometry analysis 26
3.23. Mass data evaluation for N-glycan prediction 27
3.24. RNA extraction and real-time quantitative polymerase chain reaction (PCR) assay 27
3.25. Cell cycle analysis by flow cytometry 29
3.26. Statistical analysis 29
4. Results 30
4.1. Highly metastatic HSC-3-5 cells capable of mesenchymal transformation were isolated 30
4.2. HSC-3-5 cells exhibited enhanced metastatic abilities and increased tumorigenesis in vitro and in vivo 31
4.3. Comparison of gene expression profiles between HSC-3 and HSC-3-5 cells via microarray analysis 33
4.4. AGR2 was involved in the regulation of cell migration 33
4.5. AGR2 protein expression patterns in xenografts, and tissue arrays 34
4.6. Overexpression of AGR2 was correlated with metastatic HNSCCs 35
4.7. Glycosyltransferase gene expression of HSC-3 and HSC-3-5 cells (microarray analysis) 36
4.8. N-glycan profiles of HSC-3 and HSC-3-5 cells (MALDI-TOF analysis) 37
4.9. Decreased core-fucosylation in cells and clinical tissues 38
4.10. Decreased core-fucosylation increased the positive prediction value of AGR2 with metastatic oral cancer 39
5. Discussion 41
6. Reference 48
Table information 56
Figure information 63
Supplementary Information 83
Appendices 144
1. Publications 144
2. Autobiography 145
參考文獻 [1]A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249.
[2]A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J Clin 61 (2011) 69-90.
[3]D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: a cancer journal for clinicians 55 (2005) 74-108.
[4]B.F. Parkin DM, Ferlay J, Pisani P., Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108.
[5]S.R. Jemal A, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 59 (2009) 225-249.
[6]W.S. Casiglia J, A comprehensive review of oral cancer. Gen Dent. 49 (2001) 72-82.
[7]O.T. Hivatal., Epidemiology of oral cancer. Fogorv Sz. 100 (2007) 47-52.
[8]R.K. Muwonge R, Sankila R, Thara S, Thomas G, Vinoda J, Sankaranarayanan R., Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design using incident cancer cases. Oral Oncol. 44 (2008) 446-454.
[9]statistics of cancer, in, Health of Department, Executive Yuan, Taiwain, 2009.
[10]T.Y. Seiwert, E.E. Cohen, State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92 (2005) 1341-1348.
[11]A. Zini, R. Czerninski, H.D. Sgan-Cohen, Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 39 (2010) 299-305.
[12]C.H. Peng, C.T. Liao, S.C. Peng, Y.J. Chen, A.J. Cheng, J.L. Juang, C.Y. Tsai, T.C. Chen, Y.J. Chuang, C.Y. Tang, W.P. Hsieh, T.C. Yen, A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One 6 (2011) e23452.
[13]D.S. Hsu, S.Y. Chang, C.J. Liu, C.H. Tzeng, K.J. Wu, J.Y. Kao, M.H. Yang, Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Sci 101 (2010) 1029-1037.
[14]M. Yamatoji, A. Kasamatsu, Y. Kouzu, H. Koike, Y. Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer 130 (2012) 2903-2911.
[15]R.D. Riley, W. Sauerbrei, D.G. Altman, Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. British journal of cancer 100 (2009) 1219-1229.
[16]T.M. Soland, I.J. Brusevold, Prognostic molecular markers in cancer - quo vadis? Histopathology 63 (2013) 297-308.
[17]D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144 (2011) 646-674.
[18]S. Mallett, A. Timmer, W. Sauerbrei, D.G. Altman, Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. British journal of cancer 102 (2010) 173-180.
[19]I. Malanchi, Tumour cells coerce host tissue to cancer spread. BoneKEy reports 2 (2013) 371.
[20]L. Mathot, J. Stenninger, Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer science 103 (2012) 626-631.
[21]M.R. Fein, M. Egeblad, Caught in the act: revealing the metastatic process by live imaging. Disease models & mechanisms 6 (2013) 580-593.
[22]R. Kannagi, Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconjugate journal 14 (1997) 577-584.
[23]Y.J. Kim, A. Varki, Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugate journal 14 (1997) 569-576.
[24]I. Hauselmann, L. Borsig, Altered Tumor-Cell Glycosylation Promotes Metastasis. Frontiers in oncology 4 (2014) 28.
[25]V.P. Terranova, E.S. Hujanen, D.M. Loeb, G.R. Martin, L. Thornburg, V. Glushko, Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci U S A 83 (1986) 465-469.
[26]A. Albini, Y. Iwamoto, H.K. Kleinman, G.R. Martin, S.A. Aaronson, J.M. Kozlowski, R.N. McEwan, A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer research 47 (1987) 3239-3245.
[27]Y.W. Chu, P.C. Yang, S.C. Yang, Y.C. Shyu, M.J. Hendrix, R. Wu, C.W. Wu, Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American journal of respiratory cell and molecular biology 17 (1997) 353-360.
[28]W. Zheng, P. Rosenstiel, K. Huse, C. Sina, R. Valentonyte, N. Mah, L. Zeitlmann, J. Grosse, N. Ruf, P. Nurnberg, C.M. Costello, C. Onnie, C. Mathew, M. Platzer, S. Schreiber, J. Hampe, Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes and immunity 7 (2006) 11-18.
[29]V. Brychtova, B. Vojtesek, R. Hrstka, Anterior gradient 2: a novel player in tumor cell biology. Cancer letters 304 (2011) 1-7.
[30]K. Kani, P.D. Malihi, Y. Jiang, H. Wang, Y. Wang, D.L. Ruderman, D.B. Agus, P. Mallick, M.E. Gross, Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate (2012).
[31]E. Pohler, A.L. Craig, J. Cotton, L. Lawrie, J.F. Dillon, P. Ross, N. Kernohan, T.R. Hupp, The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Molecular & cellular proteomics : MCP 3 (2004) 534-547.
[32]Z. Wang, Y. Hao, A.W. Lowe, The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 68 (2008) 492-497.
[33]K.E. Vanderlaag, S. Hudak, L. Bald, L. Fayadat-Dilman, M. Sathe, J. Grein, M.J. Janatpour, Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res 12 (2010) R32.
[34]K.S. Kornfeld R, Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 54 (1985) 631-664.
[35]P.-K. J., Methods in Enzymology: O-Glycosylation of Proteins. Methods Enzymol 405 (2005) 139-171.
[36]F.V. Morelle W, Chirat F, Michalski JC., Analysis of N- and O-linked glycans from glycoproteins using MALDI-TOF mass spectrometry. Methods Mol Biol. 534 (2009) 5-21.
[37]G.W. Hart, M.P. Housley, C. Slawson, Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446 (2007) 1017-1022.
[38]P. Van den Steen, P.M. Rudd, R.A. Dwek, G. Opdenakker, Concepts and principles of O-linked glycosylation. Critical reviews in biochemistry and molecular biology 33 (1998) 151-208.
[39]H.C. Grebner EE, Neufeld EF., Glycosylation of serine residues by a uridine diphosphate-xylose: protein xylosyltransferase from mouse mastocytoma. Arch Biochem Biophys. 116 (1966) 391-398.
[40]I.E. Stanley P, Glycosyltransferase mutants: key to new insights in glycobiology. FASEB J. 9 (1995) 1436-1444.
[41]L.B. Kirmiz C, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto S. , A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 6 (2007) 43-55.
[42]A.H. de Leoz ML, Kronewitter S, Kim J, Beecroft S, Vinall R, Miyamoto S, de Vere White R, Lam KS, Lebrilla C. , Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 25 (2008) 243-258.
[43]L.C. An HJ, A glycomics approach to the discovery of potential cancer biomarkers. Methods Mol Biol. 600 (2010) 199-213.
[44]J.W. Dennis, M. Granovsky, C.E. Warren, Glycoprotein glycosylation and cancer progression. Biochimica et biophysica acta 1473 (1999) 21-34.
[45]E.J. Fuster MM, The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. Nat Rev Cancer. 5 (2005) 526-542.
[46]K. Biskup, E.I. Braicu, J. Sehouli, C. Fotopoulou, R. Tauber, M. Berger, V. Blanchard, Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. Journal of proteome research 12 (2013) 4056-4063.
[47]I. Brockhausen, S. Narasimhan, H. Schachter, The biosynthesis of highly branched N-glycans: studies on the sequential pathway and functional role of N-acetylglucosaminyltransferases I, II, III, IV, V and VI. Biochimie 70 (1988) 1521-1533.
[48]T. Handerson, R. Camp, M. Harigopal, D. Rimm, J. Pawelek, Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 11 (2005) 2969-2973.
[49]D.J. Becker, J.B. Lowe, Fucose: biosynthesis and biological function in mammals. Glycobiology 13 (2003) 41R-53R.
[50]B. Ma, J.L. Simala-Grant, D.E. Taylor, Fucosylation in prokaryotes and eukaryotes. Glycobiology 16 (2006) 158R-184R.
[51]E. Miyoshi, K. Moriwaki, T. Nakagawa, Biological function of fucosylation in cancer biology. Journal of biochemistry 143 (2008) 725-729.
[52]K.Y. Takahashi M, Ohtsubo K, Taniguchi N. , Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res. 344 (2009) 1387-1390.
[53]Y.H. Matsumoto K, Arao T, Maegawa M, Tanaka K, Fujita Y, Shimizu C, Hanafusa T, Fujiwara Y, Nishio K., N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 99 (2008) 1611-1617.
[54]G.J. Wang X, Ihara H, Miyoshi E, Honke K, Taniguchi N., Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem. 281 (2006) 2572-2577.
[55]T.M. Osumi D, Miyoshi E, Yokoe S, Lee SH, Noda K, Nakamori S, Gu J, Ikeda Y, Kuroki Y, Sengoku K, Ishikawa M, Taniguchi N. , Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells. Cancer Sci. 100 (2009) 888-895.
[56]F. Momose, T. Araida, A. Negishi, H. Ichijo, S. Shioda, S. Sasaki, Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 18 (1989) 391-395.
[57]T. Matsui, T. Ota, Y. Ueda, M. Tanino, S. Odashima, Isolation of a highly metastatic cell line to lymph node in human oral squamous cell carcinoma by orthotopic implantation in nude mice. Oral oncology 34 (1998) 253-256.
[58]S. Azari, N. Ahmadi, M.J. Tehrani, F. Shokri, Profiling and authentication of human cell lines using short tandem repeat (STR) loci: Report from the National Cell Bank of Iran. Biologicals : journal of the International Association of Biological Standardization 35 (2007) 195-202.
[59]R. Thompson, S. Zoppis, B. McCord, An overview of DNA typing methods for human identification: past, present, and future. Methods Mol Biol 830 (2012) 3-16.
[60]C.J. Fregeau, R.M. Fourney, DNA typing with fluorescently tagged short tandem repeats: a sensitive and accurate approach to human identification. Biotechniques 15 (1993) 100-119.
[61]J.Y. Chen, Y.A. Tang, S.M. Huang, H.F. Juan, L.W. Wu, Y.C. Sun, S.C. Wang, K.W. Wu, G. Balraj, T.T. Chang, W.S. Li, H.C. Cheng, Y.C. Wang, A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71 (2011) 473-483.
[62]T. Geback, M.M. Schulz, P. Koumoutsakos, M. Detmar, TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques 46 (2009) 265-274.
[63]P. Zengel, A. Nguyen-Hoang, C. Schildhammer, R. Zantl, V. Kahl, E. Horn, mu-Slide Chemotaxis: a new chamber for long-term chemotaxis studies. BMC cell biology 12 (2011) 21.
[64]M. Gassmann, B. Grenacher, B. Rohde, J. Vogel, Quantifying Western blots: pitfalls of densitometry. Electrophoresis 30 (2009) 1845-1855.
[65]M.H. Wu, H.C. Hong, T.M. Hong, W.F. Chiang, Y.T. Jin, Y.L. Chen, Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 17 (2011) 1306-1316.
[66]H. Komatsubara, M. Umeda, N. Oku, T. Komori, Establishment of in vivo metastasis model of human adenoid cystic carcinoma: detection of metastasis by PCR with human beta-globin gene. The Kobe journal of medical sciences 48 (2002) 145-152.
[67]Y. Kariya, J. Gu, N-glycosylation of ss4 integrin controls the adhesion and motility of keratinocytes. PLoS One 6 (2011) e27084.
[68]S. Ahmadian, J. Barar, A.A. Saei, M.A. Fakhree, Y. Omidi, Cellular toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J Vis Exp (2009).
[69]F. Scholle, K.M. Bendt, N. Raab-Traub, Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74 (2000) 10681-10689.
[70]H. Tateno, S. Nakamura-Tsuruta, J. Hirabayashi, Comparative analysis of core-fucose-binding lectins from Lens culinaris and Pisum sativum using frontal affinity chromatography. Glycobiology 19 (2009) 527-536.
[71]D.C. Allred, J.M. Harvey, M. Berardo, G.M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 11 (1998) 155-168.
[72]K.R. Choudhury, K.J. Yagle, P.E. Swanson, K.A. Krohn, J.G. Rajendran, A robust automated measure of average antibody staining in immunohistochemistry images. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 58 (2010) 95-107.
[73]F.L. Greene, The American Joint Committee on Cancer: updating the strategies in cancer staging. Bulletin of the American College of Surgeons 87 (2002) 13-15.
[74]A.L. Tarentino, C.M. Gomez, T.H. Plummer, Jr., Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry 24 (1985) 4665-4671.
[75]Y.C. Liu, H.Y. Yen, C.Y. Chen, C.H. Chen, P.F. Cheng, Y.H. Juan, C.H. Chen, K.H. Khoo, C.J. Yu, P.C. Yang, T.L. Hsu, C.H. Wong, Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America 108 (2011) 11332-11337.
[76]A. Dell, A.J. Reason, K.H. Khoo, M. Panico, R.A. McDowell, H.R. Morris, Mass spectrometry of carbohydrate-containing biopolymers. Methods in enzymology 230 (1994) 108-132.
[77]N.P. Price, Permethylation linkage analysis techniques for residual carbohydrates. Applied biochemistry and biotechnology 148 (2008) 271-276.
[78]Z. Lin, D.M. Lubman, Permethylated N-glycan analysis with mass spectrometry. Methods Mol Biol 1007 (2013) 289-300.
[79]A. Ceroni, K. Maass, H. Geyer, R. Geyer, A. Dell, S.M. Haslam, GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. Journal of proteome research 7 (2008) 1650-1659.
[80]M. Duda, A. Gasinska, E.L. Gregoraszczuk, Flow cytometric cell cycle analysis of two subpopulations of porcine granulosa cells. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 107 (1999) 203-207.
[81]T.M. Clayton, J.P. Whitaker, R. Sparkes, P. Gill, Analysis and interpretation of mixed forensic stains using DNA STR profiling. Forensic science international 91 (1998) 55-70.
[82]K. Yoshino, E. Iimura, K. Saijo, S. Iwase, K. Fukami, T. Ohno, Y. Obata, Y. Nakamura, Essential role for gene profiling analysis in the authentication of human cell lines. Human cell 19 (2006) 43-48.
[83]H. Ihara, Y. Ikeda, S. Toma, X. Wang, T. Suzuki, J. Gu, E. Miyoshi, T. Tsukihara, K. Honke, A. Matsumoto, A. Nakagawa, N. Taniguchi, Crystal structure of mammalian alpha1,6-fucosyltransferase, FUT8. Glycobiology 17 (2007) 455-466.
[84]D.L. Barraclough, A. Platt-Higgins, S. de Silva Rudland, R. Barraclough, J. Winstanley, C.R. West, P.S. Rudland, The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. The American journal of pathology 175 (2009) 1848-1857.
[85]Y. Jing, Z. Han, S. Zhang, Y. Liu, L. Wei, Epithelial-Mesenchymal Transition in tumor microenvironment. Cell & bioscience 1 (2011) 29.
[86]E.W. Thompson, D.F. Newgreen, D. Tarin, Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65 (2005) 5991-5995; discussion 5995.
[87]L. Dumartin, H.J. Whiteman, M.E. Weeks, D. Hariharan, B. Dmitrovic, C.A. Iacobuzio-Donahue, T.A. Brentnall, M.P. Bronner, R.M. Feakins, J.F. Timms, C. Brennan, N.R. Lemoine, T. Crnogorac-Jurcevic, AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer research 71 (2011) 7091-7102.
[88]Z.S. Wu, Q. Wu, X.D. Ding, H.Q. Wang, Y.X. Shen, S.Y. Fang, [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance]. Zhonghua bing li xue za zhi Chinese journal of pathology 37 (2008) 109-113.
[89]L. Sweeny, Z. Liu, B.D. Bush, Y. Hartman, T. Zhou, E.L. Rosenthal, CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma. Experimental cell research 318 (2012) 1788-1798.
[90]A. Higa, A. Mulot, F. Delom, M. Bouchecareilh, D.T. Nguyen, D. Boismenu, M.J. Wise, E. Chevet, Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. The Journal of biological chemistry 286 (2011) 44855-44868.
[91]K. Kani, P.D. Malihi, Y. Jiang, H. Wang, Y. Wang, D.L. Ruderman, D.B. Agus, P. Mallick, M.E. Gross, Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. The Prostate 73 (2013) 306-315.
[92]S. Darb-Esfahani, F. Fritzsche, G. Kristiansen, W. Weichert, J. Sehouli, I. Braicu, M. Dietel, C. Denkert, Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma. Virchows Archiv : an international journal of pathology 461 (2012) 109-116.
[93]F.R. Fritzsche, E. Dahl, A. Dankof, M. Burkhardt, S. Pahl, I. Petersen, M. Dietel, G. Kristiansen, Expression of AGR2 in non small cell lung cancer. Histology and histopathology 22 (2007) 703-708.
[94]S.J. Ichwan, S. Yamada, P. Sumrejkanchanakij, E. Ibrahim-Auerkari, K. Eto, M.A. Ikeda, Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 25 (2006) 1216-1224.
[95]C.H. Liao, S.C. Yeh, Y.H. Huang, R.N. Chen, M.M. Tsai, W.J. Chen, H.C. Chi, P.J. Tai, C.J. Liao, S.M. Wu, W.L. Cheng, L.M. Pai, K.H. Lin, Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr Relat Cancer 17 (2010) 99-111.
[96]X. Qian, C. Li, B. Pang, M. Xue, J. Wang, J. Zhou, Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One 7 (2012) e37225.
[97]J. Zhou, C. Bi, L.L. Cheong, S. Mahara, S.C. Liu, K.G. Tay, T.L. Koh, Q. Yu, W.J. Chng, The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118 (2011) 2830-2839.
[98]P.D. Rye, R.A. Walker, Analysis of glycoproteins released from benign and malignant human breast: changes in size and fucosylation with malignancy. European journal of cancer & clinical oncology 25 (1989) 65-72.
[99]E. Gruszewska, L. Chrostek, [The alterations of glycosylation in malignant diseases]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 34 (2013) 58-61.
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2017-05-02起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2017-05-02起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw